title: Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients.
abstract: Pefloxacin was used to treat nosocomial pulmonary infections in 46 mechanically ventilated patients. All patients had one or more underlying diseases and were given pefloxacin at a dose of 800 mg or 1200 mg daily in two or three divided doses. The commonest bacterial isolates were Staphylococcus aureus, Pseudomonas aeruginosa and enterobacteria. Of these patients, 33 (72%) showed a favourable response, one patient relapsed and 12 (26%) were considered failures. Superinfections occurred in 10 (22%). Of the 62 isolated potential pathogens, 53 (85%) were completely eradicated. Side effects were mild and treatment was withdrawn in only three patients. Pefloxacin can be considered as a possible therapeutic agent for the treatment of nosocomial pulmonary infections.
authors.affiliation: Hôpital Sainte-Marguerite, Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: F
authors.initials: F
authors.lastname: Gouin
authors.forename: F
authors.initials: F
authors.lastname: Fourrier
authors.forename: W
authors.initials: W
authors.lastname: Junginger
authors.forename: B L
authors.initials: BL
authors.lastname: Prieur
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001996:Bronchopneumonia / Q000188:drug therapy*; D003428:Cross Infection / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015366:Pefloxacin; D011014:Pneumonia / Q000188:drug therapy*; D011446:Prospective Studies; D012121:Respiration, Artificial
chemical_list: D015366:Pefloxacin; D009643:Norfloxacin